Suscribirse

ANTIBIOTIC RESISTANCE - 06/09/11

Doi : 10.1016/S0025-7125(05)70295-9 
Burke A. Cunha, MD *

Resumen

Antibiotic resistance with some microorganisms has become a worldwide concern. After World War II, penicillin resistance among gonococci and staphylococcal strains was first noted.177 Methicillinresistant Staphylococcus aureus (MRSA) emerged in the 1970s. Penicillinase-producing Neisseria gonorrhoeae (PPNG) strains constitute most gonococcal strains from many geographical locations.3, 42, 78, 79 Aminoglycoside-resistant Pseudomonas aeruginosa was first noted after the widespread use of gentamicin.

Ceftazidime-resistant and ciprofloxacin-resistant P. aeruginosa remain a concern today. Resistance among respiratory pathogens (e.g., Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) has increased since the 1970s.8, 33, 43, 85, 97, 114, 146 Virtually all strains of M. catarrhalis are β-lactamase–producing strains resistant to penicillin and other β-lactam antibiotics. Ampicillin-resistant H. influenzae have increased and now are common in many areas worldwide.164, 165 Relative penicillin-resistant pneumococci have been reported worldwide. Most penicillin resistance is relative, and highly penicillin-resistant strains remain uncommon.*

Among certain organisms, antibiotic resistance has not been a problem. There is no resistance among the atypical pulmonary pathogens (e.g., Legionella, Mycoplasma pneumoniae, Chlamydia pneumoniae, Q fever, tularemia, or psittacosis). Bacteroides fragilis and anaerobic organisms, in general, have not shown any clinically significant resistance.133 Rickettsia and spirochetal organisms have not developed resistance.15, 63, 78, 98, 112, 173, 177

A distinction must be made between increased prevalence versus the emergence of resistant organisms, which is the case with enterococci. In the past, most enterococci were of the Enterococcus faecalis variety (i.e., sensitive to ampicillin and vancomycin). Enterococcus faecium, which constitutes nearly all vancomycin-resistant enterococci (VRE) strains, is an example of increased prevalence of this organism to be distinguished from increasing vancomycin resistance. VRE is no more resistant now than it was previously, but it is more prevalent now. VRE is not an example of increasing antibiotic resistance but rather a change in the selective pressures of the fecal flora favoring the widespread emergence of VRE as a colonizer or cause of infection in many hospitals.*

Certain organisms always have been highly resistant or resistant to multiple antibiotics (e.g., Acinetobacter baumanii, non-aeruginosa Pseudomonas [Burkholderia, Stenotrophomonas]). Frequently, Acinetobacter is reported in the literature as being highly resistant or multiresistant to several antibiotics.7, 9, 35, 103, 140, 162, 185 A. baumanii was never very sensitive to many antibiotics.

Terminology is important in describing and defining resistance. Changes in antibiotic breakpoints defining sensitive, intermediate, or resistant strains have profound effects on the apparent incidence of antibiotic resistance.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Burke A. Cunha, MD, Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501


© 2000  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 84 - N° 6

P. 1407-1429 - novembre 2000 Regresar al número
Artículo precedente Artículo precedente
  • ANTIBIOTIC SYNERGY AND ANTAGONISM
  • Jacques F. Acar
| Artículo siguiente Artículo siguiente
  • ANTIMICROBIAL PHARMACODYNAMICS
  • Paul G. Ambrose, Robert C. Owens, Dennis Grasela

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.